JP2016538313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538313A5 JP2016538313A5 JP2016535053A JP2016535053A JP2016538313A5 JP 2016538313 A5 JP2016538313 A5 JP 2016538313A5 JP 2016535053 A JP2016535053 A JP 2016535053A JP 2016535053 A JP2016535053 A JP 2016535053A JP 2016538313 A5 JP2016538313 A5 JP 2016538313A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- halogen
- hydrogen
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 120
- 229910052736 halogen Chemical group 0.000 claims description 102
- 239000001257 hydrogen Substances 0.000 claims description 92
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 92
- 150000002367 halogens Chemical group 0.000 claims description 75
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 28
- -1 cyano, hydroxyl Chemical group 0.000 claims description 27
- 125000004429 atom Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- YPHQUSNPXDGUHL-UHFFFAOYSA-N n-methylprop-2-enamide Chemical compound CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 claims description 6
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- NUJVYNDJMXNZNK-NRFANRHFSA-N 2-[3-[6-amino-5-[[(2S)-1-prop-2-enoylazetidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-(hydroxymethyl)phenyl]-6-cyclopropyl-3,4-dihydroisoquinolin-1-one Chemical compound Nc1ncnc(c1OC[C@@H]1CCN1C(=O)C=C)-c1cc(F)cc(N2CCc3cc(ccc3C2=O)C2CC2)c1CO NUJVYNDJMXNZNK-NRFANRHFSA-N 0.000 claims description 2
- JJMARAVUCXEXPI-QFIPXVFZSA-N 2-[3-[6-amino-5-[[(2S)-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-(hydroxymethyl)phenyl]-6-cyclopropyl-3,4-dihydroisoquinolin-1-one Chemical compound Nc1ncnc(c1OC[C@@H]1CCCN1C(=O)C=C)-c1cc(F)cc(N2CCc3cc(ccc3C2=O)C2CC2)c1CO JJMARAVUCXEXPI-QFIPXVFZSA-N 0.000 claims description 2
- HMNGHDQWQAJIPP-XZOQPEGZSA-N 2-[3-[6-amino-5-[[(2S,4R)-4-methoxy-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-(hydroxymethyl)phenyl]-6-cyclopropyl-3,4-dihydroisoquinolin-1-one Chemical compound CO[C@@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(N3CCc4cc(ccc4C3=O)C3CC3)c2CO)N(C1)C(=O)C=C HMNGHDQWQAJIPP-XZOQPEGZSA-N 0.000 claims description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 2
- PBCHDYZOFFYTSM-RBUKOAKNSA-N C(C=C)(=O)N1[C@@H](C[C@H](C1)OC)COC=1C(=NC=NC=1N)C=1C(=C(C=C(C=1)F)C=1C(=C(C(=O)N)C=CC=1C1CC1)F)C Chemical compound C(C=C)(=O)N1[C@@H](C[C@H](C1)OC)COC=1C(=NC=NC=1N)C=1C(=C(C=C(C=1)F)C=1C(=C(C(=O)N)C=CC=1C1CC1)F)C PBCHDYZOFFYTSM-RBUKOAKNSA-N 0.000 claims description 2
- GOGOVJFVUIFNDX-UHFFFAOYSA-N C(C=C)(=O)NCCOC1=NC(=CC(=N1)C1(CC=C(C(=C1)C=1C(=C(C(=O)N)C=CC1C1CC1)F)C)F)N Chemical compound C(C=C)(=O)NCCOC1=NC(=CC(=N1)C1(CC=C(C(=C1)C=1C(=C(C(=O)N)C=CC1C1CC1)F)C)F)N GOGOVJFVUIFNDX-UHFFFAOYSA-N 0.000 claims description 2
- ROYGBUGGEVOCCJ-UHFFFAOYSA-N N-[2-[4-amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2-yl)phenyl]pyrimidin-5-yl]oxyethyl]-N-methylprop-2-enamide Chemical compound CN(CCOc1c(N)ncnc1-c1cccc(c1)-n1ccc2cc(cc(F)c2c1=O)C1CC1)C(=O)C=C ROYGBUGGEVOCCJ-UHFFFAOYSA-N 0.000 claims description 2
- ZFUQKYYJMUPMTI-UHFFFAOYSA-N N-[2-[4-amino-6-[3-[(4-cyclopropyl-2-fluorobenzoyl)amino]-5-fluoro-2-methylphenyl]pyrimidin-5-yl]oxyethyl]-N-methyloxirane-2-carboxamide Chemical compound CN(CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C1CO1 ZFUQKYYJMUPMTI-UHFFFAOYSA-N 0.000 claims description 2
- OSLWRSOLKHYZCC-UHFFFAOYSA-N N-[3-[6-amino-5-(1-prop-2-enoylazetidin-3-yl)oxypyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC1CN(C1)C(=O)C=C OSLWRSOLKHYZCC-UHFFFAOYSA-N 0.000 claims description 2
- WWPRHRSBBBVQRE-HNNXBMFYSA-N N-[3-[6-amino-5-[(2S)-2-(but-2-ynoylamino)propoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound NC1=C(C(=NC=N1)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C)OC[C@H](C)NC(C#CC)=O WWPRHRSBBBVQRE-HNNXBMFYSA-N 0.000 claims description 2
- DTUJVUIDYMFIAW-AWEZNQCLSA-N N-[3-[6-amino-5-[(2S)-2-(prop-2-enoylamino)propoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C(C=C)(=O)N[C@H](COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C)C DTUJVUIDYMFIAW-AWEZNQCLSA-N 0.000 claims description 2
- CLFDGAFGHVOAPE-ONEGZZNKSA-N N-[3-[6-amino-5-[1-[(E)-but-2-enoyl]azetidin-3-yl]oxypyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C1N(C(=O)/C=C/C)CC1Oc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C CLFDGAFGHVOAPE-ONEGZZNKSA-N 0.000 claims description 2
- LBPYBURZJMWWDQ-SNAWJCMRSA-N N-[3-[6-amino-5-[2-[[(E)-4-methoxybut-2-enoyl]-methylamino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound COC\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C LBPYBURZJMWWDQ-SNAWJCMRSA-N 0.000 claims description 2
- MAEVSXHQLPMRFL-SNAWJCMRSA-N N-[3-[6-amino-5-[2-[[(E)-but-2-enoyl]-methylamino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C MAEVSXHQLPMRFL-SNAWJCMRSA-N 0.000 claims description 2
- VNHKOUCVWYOOAC-LJQANCHMSA-N N-[3-[6-amino-5-[[(2R)-1-prop-2-enoylazetidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C(C=C)(=O)N1[C@H](CC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C VNHKOUCVWYOOAC-LJQANCHMSA-N 0.000 claims description 2
- MRMUBBWFULSDKQ-RPBOFIJWSA-N N-[3-[6-amino-5-[[(2R,3S)-3-methoxy-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound CO[C@H]1CCN([C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C=C MRMUBBWFULSDKQ-RPBOFIJWSA-N 0.000 claims description 2
- VNHKOUCVWYOOAC-IBGZPJMESA-N N-[3-[6-amino-5-[[(2S)-1-prop-2-enoylazetidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C(C=C)(=O)N1[C@@H](CC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C VNHKOUCVWYOOAC-IBGZPJMESA-N 0.000 claims description 2
- ZVHBHHORKZBNIT-UWJYYQICSA-N N-[3-[6-amino-5-[[(2S,4R)-4-cyano-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@H](CN1C(=O)C=C)C#N ZVHBHHORKZBNIT-UWJYYQICSA-N 0.000 claims description 2
- MYNSOSQDEAAOFJ-UXHICEINSA-N N-[3-[6-amino-5-[[(2S,4R)-4-fluoro-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@@H](F)CN1C(=O)C=C MYNSOSQDEAAOFJ-UXHICEINSA-N 0.000 claims description 2
- NOBVNQWDJSXGNG-SFTDATJTSA-N N-[3-[6-amino-5-[[(2S,4S)-4-methoxy-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound CO[C@H]1C[C@@H](COc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(cc3F)C3CC3)c2C)N(C1)C(=O)C=C NOBVNQWDJSXGNG-SFTDATJTSA-N 0.000 claims description 2
- YLXWLGWXHPGIMD-GOSISDBHSA-N N-[3-[6-amino-5-[[(3R)-1-prop-2-enoylpiperidin-3-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C(C=C)(=O)N1C[C@@H](CCC1)COC=1C(=NC=NC1N)C=1C(=C(C=C(C1)F)NC(C1=C(C=C(C=C1)C1CC1)F)=O)C YLXWLGWXHPGIMD-GOSISDBHSA-N 0.000 claims description 2
- YYRLWYMBOAJKGR-UHFFFAOYSA-N N-[3-[6-amino-5-[[1-(prop-2-enoylamino)cyclopropyl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OCC1(CC1)NC(=O)C=C YYRLWYMBOAJKGR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- QTZCKDFHDJVFRD-UHFFFAOYSA-N n-(2-fluoroethyl)prop-2-enamide Chemical compound FCCNC(=O)C=C QTZCKDFHDJVFRD-UHFFFAOYSA-N 0.000 claims description 2
- ZJMZNFQDSWTHLP-FQEVSTJZSA-N n-[3-[6-amino-5-[[(2s)-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound C1=C(F)C=C(C=2C(=C(N)N=CN=2)OC[C@H]2N(CCC2)C(=O)C=C)C(C)=C1NC(=O)C(C(=C1)F)=CC=C1C1CC1 ZJMZNFQDSWTHLP-FQEVSTJZSA-N 0.000 claims description 2
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 63
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 125000005466 alkylenyl group Chemical group 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- ZVHBHHORKZBNIT-UTKZUKDTSA-N N-[3-[6-amino-5-[[(2S,4S)-4-cyano-1-prop-2-enoylpyrrolidin-2-yl]methoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide Chemical compound Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC[C@@H]1C[C@@H](CN1C(=O)C=C)C#N ZVHBHHORKZBNIT-UTKZUKDTSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195081 | 2013-11-29 | ||
| EP13195081.8 | 2013-11-29 | ||
| PCT/IB2014/066422 WO2015079417A1 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018094772A Division JP6667573B2 (ja) | 2013-11-29 | 2018-05-16 | 新規なアミノピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538313A JP2016538313A (ja) | 2016-12-08 |
| JP2016538313A5 true JP2016538313A5 (https=) | 2017-10-26 |
| JP6342495B2 JP6342495B2 (ja) | 2018-06-13 |
Family
ID=49674216
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535053A Active JP6342495B2 (ja) | 2013-11-29 | 2014-11-28 | 新規なアミノピリミジン誘導体 |
| JP2018094772A Active JP6667573B2 (ja) | 2013-11-29 | 2018-05-16 | 新規なアミノピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018094772A Active JP6667573B2 (ja) | 2013-11-29 | 2018-05-16 | 新規なアミノピリミジン誘導体 |
Country Status (42)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| ES2876974T3 (es) * | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| EP4643874A3 (en) | 2015-12-22 | 2026-02-11 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| EP3487878A4 (en) | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | CD229-CAR-T CELLS AND METHOD FOR USE THEREOF |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| BR112019011065A2 (pt) | 2016-12-03 | 2019-10-01 | Juno Therapeutics Inc | métodos para determinação da dosagem de células t car |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| JP2020526194A (ja) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| SG11202003501XA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| TWI694995B (zh) * | 2017-11-06 | 2020-06-01 | 美商美國禮來大藥廠 | Btk抑制劑化合物 |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途 |
| MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| IL312413B2 (en) | 2018-08-29 | 2026-01-01 | Acerta Pharma Bv | Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| IL283218B2 (en) | 2018-11-16 | 2025-11-01 | Juno Therapeutics Inc | Dosing methods of engineered T cells for the treatment of malignant B cells |
| PT3886875T (pt) | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
| SG11202107976SA (en) | 2019-01-29 | 2021-08-30 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| BR112021023110A2 (pt) * | 2019-05-23 | 2022-04-12 | Novartis Ag | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton |
| RS67141B1 (sr) * | 2019-05-23 | 2025-09-30 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije |
| CN113840821A (zh) * | 2019-05-23 | 2021-12-24 | 诺华股份有限公司 | Btk抑制剂的晶型 |
| WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
| EP4081514A1 (en) * | 2019-12-23 | 2022-11-02 | Biogen MA Inc. | Btk inhibitors |
| JP2023522857A (ja) | 2020-04-10 | 2023-06-01 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用 |
| JP7545570B2 (ja) | 2020-08-14 | 2024-09-04 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
| WO2022033569A1 (zh) * | 2020-08-14 | 2022-02-17 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
| MX2023008671A (es) | 2021-01-26 | 2023-09-25 | Novartis Ag | Composicion farmaceutica. |
| CN116782888A (zh) * | 2021-01-26 | 2023-09-19 | 诺华股份有限公司 | 药物组合物 |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| JP7564347B2 (ja) * | 2021-09-03 | 2024-10-08 | ノバルティス アーゲー | 多発性硬化症を治療するためのｌｏｕ０６４ |
| US20250032488A1 (en) | 2021-12-14 | 2025-01-30 | Novartis Ag | Methods of treatment using lou064 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| EP4543923A1 (en) | 2022-06-22 | 2025-04-30 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| JP2025525937A (ja) | 2022-08-05 | 2025-08-07 | ジュノー セラピューティクス インコーポレイテッド | Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体 |
| CN119998265A (zh) * | 2022-09-30 | 2025-05-13 | 诺华股份有限公司 | 用于生产瑞布替尼的合成方法和中间体 |
| KR20250135354A (ko) | 2022-12-13 | 2025-09-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도 |
| WO2025061148A1 (zh) * | 2023-09-22 | 2025-03-27 | 江苏恒瑞医药股份有限公司 | 杂芳基类化合物、其制备方法及其在医药上的应用 |
| CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
| US20250243170A1 (en) | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
| WO2025210469A2 (en) | 2024-04-02 | 2025-10-09 | Novartis Ag | Process of preparing remibrutinib substantially free of nitrosamine impurity |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| AU2002236692A1 (en) | 2000-10-23 | 2002-05-21 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use |
| EP2070921A1 (en) | 2000-11-07 | 2009-06-17 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2506432A1 (en) | 2002-12-09 | 2004-06-24 | Robert A. Kirken | Methods for selectively inhibiting janus tyrosine kinase 3 (jak3) |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| CL2004001120A1 (es) | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| DK1704145T3 (da) | 2004-01-12 | 2012-09-24 | Ym Biosciences Australia Pty | Selektive kinaseinhibitorer |
| MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| JP5832721B2 (ja) | 2007-03-14 | 2015-12-16 | バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． | 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物 |
| CA2723237A1 (en) | 2008-05-06 | 2009-11-12 | Peter A. Blomgren | Substituted amides, method of making, and use as btk inhibitors |
| PE20110164A1 (es) | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2010122038A1 (en) | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| MX2012009851A (es) * | 2010-02-26 | 2012-09-12 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas. |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| MX2014000130A (es) | 2011-06-28 | 2014-05-01 | Pharmacyclics Inc | Procedimientos y composiciones para la inhibicion de resorcion osea. |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| US9273317B2 (en) | 2011-08-09 | 2016-03-01 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells |
| MX391121B (es) | 2011-10-19 | 2025-03-19 | Pharmacyclics Llc | Uso de inhibidores de la tirosina cinasa de bruton (btk). |
| US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
| JP5832664B2 (ja) | 2011-12-09 | 2015-12-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトン型チロシンキナーゼの阻害剤 |
| KR20140131955A (ko) | 2012-03-09 | 2014-11-14 | 카나 바이오사이언스 인코포레이션 | 신규 트리아진 유도체 |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2013173518A1 (en) | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| SG11201500499TA (en) | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2014055928A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/ar active
- 2014-11-27 UY UY0001035858A patent/UY35858A/es active IP Right Grant
- 2014-11-27 AR ARP140104439A patent/AR098549A1/es active IP Right Grant
- 2014-11-28 PL PL17191467T patent/PL3299368T3/pl unknown
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/es unknown
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/hu unknown
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 MX MX2016006908A patent/MX367911B/es active IP Right Grant
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/pt active IP Right Grant
- 2014-11-28 HR HRP20171999TT patent/HRP20171999T1/hr unknown
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 TW TW103141506A patent/TWI652261B/zh active
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 RS RS20200550A patent/RS60251B1/sr unknown
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
- 2014-11-28 PL PL14821285T patent/PL3074386T3/pl unknown
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/ko active Active
- 2014-11-28 PT PT171914674T patent/PT3299368T/pt unknown
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/da active
- 2014-11-28 RS RS20171206A patent/RS56657B1/sr unknown
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/hr unknown
- 2014-11-28 SI SI201431570T patent/SI3299368T1/sl unknown
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/hu unknown
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/lt unknown
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 UA UAA201603623A patent/UA117256C2/uk unknown
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/ko active Active
- 2014-11-28 PT PT201589611T patent/PT3689865T/pt unknown
- 2014-11-28 ES ES23161775T patent/ES3040769T3/es active Active
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/zh active Active
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/lt unknown
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 ES ES20158961T patent/ES2947770T3/es active Active
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/hu unknown
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/lt unknown
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en not_active Ceased
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/es active Active
- 2014-11-28 RS RS20230437A patent/RS64275B1/sr unknown
- 2014-11-28 PT PT148212855T patent/PT3074386T/pt unknown
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/zh active Active
- 2014-11-28 EP EP25181626.0A patent/EP4606377A3/en active Pending
- 2014-11-28 EP EP23161775.4A patent/EP4219478B1/en active Active
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/fi active
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/da active
- 2014-11-28 SI SI201432031T patent/SI3689865T1/sl unknown
- 2014-11-28 CU CU2016000078A patent/CU24384B1/es unknown
- 2014-11-28 MA MA39055A patent/MA39055B1/fr unknown
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/ja active Active
- 2014-11-28 ES ES17191467T patent/ES2791525T3/es active Active
- 2014-11-28 EA EA201691125A patent/EA031218B1/ru not_active IP Right Cessation
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/pl unknown
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791B1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/es unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/es unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/es unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/es unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/el unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/ja active Active
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/hr unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/el unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en not_active Abandoned
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538313A5 (https=) | ||
| SI3074386T1 (en) | New aminopyrimidine derivatives | |
| JP2014513110A5 (https=) | ||
| JP2015514808A5 (https=) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2014530900A5 (https=) | ||
| JP2017528487A5 (https=) | ||
| JP2019510796A5 (https=) | ||
| JP2016523974A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2016506962A5 (https=) | ||
| HRP20220990T1 (hr) | 3-supstituirane propionske kiseline kao inhibitori alfa v integrina | |
| JP2014526549A5 (https=) | ||
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2012501312A5 (https=) | ||
| JP2016517878A5 (https=) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2014508804A5 (https=) | ||
| JP2019505595A5 (https=) | ||
| RU2014131058A (ru) | Средство, усиливающее действие противоопухолевых средств | |
| JP2017526724A5 (https=) | ||
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 |